{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:37:30Z","timestamp":1783489050541,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00262-018-2189-x","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T02:52:45Z","timestamp":1529895165000},"page":"1297-1303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-935X","authenticated-orcid":false,"given":"Georgia","family":"Karpathiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Chauleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirine","family":"Hathroubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Habougit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Peoc\u2019h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"issue":"10","key":"2189_CR1","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/jcp.53.10.742","volume":"53","author":"J Lloyd","year":"2000","unstructured":"Lloyd J, Flanagan AM (2000) Mammary and extramammary Paget\u2019s disease. J Clin Pathol 53(10):742\u2013749","journal-title":"J Clin Pathol"},{"issue":"9","key":"2189_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1097\/PAS.0b013e318259ef7f","volume":"36","author":"X Duan","year":"2012","unstructured":"Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM et al (2012) Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol 36(9):1353\u20131358","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2189_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.det.2010.08.002","volume":"28","author":"C Lam","year":"2010","unstructured":"Lam C, Funaro D (2010) Extramammary Paget\u2019s disease: summary of current knowledge. Dermatol Clin 28(4):807\u2013826","journal-title":"Dermatol Clin"},{"issue":"1","key":"2189_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PAP.0b013e318202eba5","volume":"18","author":"DV Kazakov","year":"2011","unstructured":"Kazakov DV, Spagnolo DV, Kacerovska D, Michal M (2011) Lesions of anogenital mammary-like glands. Adv Anat Pathol 18(1):1\u201328","journal-title":"Adv Anat Pathol"},{"issue":"11","key":"2189_CR5","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/DAD.0000000000000552","volume":"38","author":"AM Konstantinova","year":"2016","unstructured":"Konstantinova AM, Shelekhova KV, Stewart CJ, Spagnolo DV, Kutzner H, Kacerovska D et al (2016) Depth and patterns of adnexal involvement in primary extramammary (anogenital) Paget disease: a study of 178 lesions from 146 patients. Am J Dermatopathol 38(11):802\u2013808","journal-title":"Am J Dermatopathol"},{"key":"2189_CR6","doi-asserted-by":"crossref","unstructured":"Edey KA, Allan E, Murdoch JB, Cooper S, Bryant A (2013) Interventions for the treatment of Paget\u2019s disease of the vulva. Cochrane Database Syst Rev (Wiley, Chichester)","DOI":"10.1002\/14651858.CD009245.pub2"},{"issue":"1","key":"2189_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ygyno.2016.04.028","volume":"142","author":"RA Cowan","year":"2016","unstructured":"Cowan RA, Black DR, Hoang LN, Park KJ, Soslow RA, Backes FJ et al (2016) A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget\u2019s disease. Gynecol Oncol 142(1):139\u2013143","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2189_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/bjd.15253","volume":"176","author":"J Fletcher","year":"2017","unstructured":"Fletcher J, Haniffa M (2017) Mechanisms of immune evasion in extramammary Paget disease. Br J Dermatol 176(2):293\u2013294","journal-title":"Br J Dermatol"},{"issue":"2","key":"2189_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/bjd.14864","volume":"176","author":"T Fujimura","year":"2017","unstructured":"Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Hidaka T, Aiba S (2017) Possible mechanisms of the crosstalk between Langerhans cells and regulatory T cells in extramammary Paget disease by receptor activator of nuclear factor kappa B (RANK) ligand\/RANK pathways. Br J Dermatol 176(2):387\u2013394","journal-title":"Br J Dermatol"},{"issue":"12","key":"2189_CR10","doi-asserted-by":"publisher","first-page":"19310","DOI":"10.18632\/oncotarget.14242","volume":"8","author":"G Karpathiou","year":"2017","unstructured":"Karpathiou G, Casteillo F, Giroult JB, Forest F, Fournel P, Monaya A et al (2017) Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics. Oncotarget 8(12):19310\u201319322","journal-title":"Oncotarget"},{"issue":"4","key":"2189_CR11","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.4081\/rt.2016.6804","volume":"8","author":"L Padrnos","year":"2016","unstructured":"Padrnos L, Karlin N, Halfdanarson TR (2016) Mayo Clinic Cancer Center experience of metastatic extramammary Paget disease 1998\u20132012. Rare Tumors 8(4):6804","journal-title":"Rare Tumors"},{"key":"2189_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.gore.2016.12.010","volume":"19","author":"CO Onaiwu","year":"2017","unstructured":"Onaiwu CO, Salcedo MP, Pessini SA, Munsell MF, Euscher EE, Reed KE et al (2017) Paget\u2019s disease of the vulva: a review of 89 cases. Gynecol Oncol Rep 19:46\u201349","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"2189_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2011.03.033","volume":"122","author":"ISC Jones","year":"2011","unstructured":"Jones ISC, Crandon A, Sanday K (2011) Paget\u2019s disease of the vulva: diagnosis and follow-up key to management; a retrospective study of 50 cases from Queensland. Gynecol Oncol 122(1):42\u201344","journal-title":"Gynecol Oncol"},{"key":"2189_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.gde.2013.11.008","volume":"24","author":"S Budhu","year":"2014","unstructured":"Budhu S, Wolchok J, Merghoub T (2014) The importance of animal models in tumor immunity and immunotherapy. Curr Opin Genet Dev 24:46\u201351","journal-title":"Curr Opin Genet Dev"},{"issue":"2","key":"2189_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ygyno.2010.10.019","volume":"120","author":"JZ Press","year":"2011","unstructured":"Press JZ, Allison KH, Garcia R, Everett EN, Pizer E, Swensen RE et al (2011) FOXP3+ regulatory T-cells are abundant in vulvar Paget\u2019s disease and are associated with recurrence. Gynecol Oncol 120(2):296\u2013299","journal-title":"Gynecol Oncol"},{"issue":"28","key":"2189_CR16","doi-asserted-by":"publisher","first-page":"46204","DOI":"10.18632\/oncotarget.17581","volume":"8","author":"JJ Sznurkowski","year":"2017","unstructured":"Sznurkowski JJ, \u017bawrocki A, Biernat W (2017) Local immune response depends on p16INK4a status of primary tumor in vulvar squamous cell carcinoma. Oncotarget 8(28):46204\u201346210","journal-title":"Oncotarget"},{"issue":"10","key":"2189_CR17","first-page":"1099","volume":"7","author":"CR Alcazar Gil Del","year":"2017","unstructured":"Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F et al (2017) Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov 7(10):1099\u20131115","journal-title":"Cancer Discov"},{"issue":"17","key":"2189_CR18","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1158\/1078-0432.CCR-17-0743","volume":"23","author":"S Hendry","year":"2017","unstructured":"Hendry S, Pang JMB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG et al (2017) Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features. Clin Cancer Res 23(17):5210\u20135217","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2189_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/modpathol.2015.158","volume":"29","author":"E Thompson","year":"2016","unstructured":"Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN et al (2016) The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol 29(3):249\u2013258","journal-title":"Mod Pathol"},{"issue":"4","key":"2189_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/imm.12101","volume":"139","author":"W Yang","year":"2013","unstructured":"Yang W, Song Y, Lu Y-L, Sun J-Z, Wang H-W (2013) Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology 139(4):513\u2013522","journal-title":"Immunology"},{"issue":"6230","key":"2189_CR21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124\u2013128","journal-title":"Science"},{"key":"2189_CR22","unstructured":"https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm560167.htm"},{"issue":"26","key":"2189_CR23","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L et al (2016) PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374(26):2542\u20132552","journal-title":"N Engl J Med"},{"issue":"19","key":"2189_CR24","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2189-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2189-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2189-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T08:43:49Z","timestamp":1561452229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2189-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2189-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"17 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Local Ethics Committee of the University Hospital of Saint-Etienne approved the study (IRBN132018\/CHUSTE).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The acquisition of written informed consent was waived by the institutional review board given the retrospective nature of the study and the anonymization of all data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}